FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165648618> ?p ?o ?g. }

• W3165648618 endingPage "55" @default.
• W3165648618 startingPage "49" @default.
• W3165648618 abstract "Whether trastuzumab use beyond disease progression is beneficial in second-line treatment for patients with unresectable human epidermal growth factor receptor 2 (HER2)-positive gastric cancer remains to be elucidated. We conducted this phase II study to assess whether trastuzumab plus docetaxel was effective for patients with previously treated advanced HER2-positive gastric cancer. This trial was a single-arm, open-label, multicenter, phase II study, conducted by Tohoku Clinical Oncology Research and Education Society (T-CORE). Patients aged 20 years or older who had advanced HER2-positive gastric cancer and were refractory to trastuzumab, fluoropyrimidine, and cisplatin were enrolled. Patients were treated with 6 mg/kg trastuzumab and 60 mg/m2 docetaxel every 3 weeks. The primary endpoint was the overall response rate. The threshold overall response rate was estimated to be at 15%. Secondary endpoints were progression-free survival, 6-month survival rate, overall survival, and toxicities. A total of 27 patients were enrolled from 7 hospitals. The median age was 67 years. Partial response was seen in 3 patients among the 26 evaluated patients. The overall response rate was at 11.5% (90% confidence interval 1.2%-21.8%). The median progression-free survival was 3.2 months, the 6-month survival rate was 85%, and the median overall survival was 11.6 months. Febrile neutropenia was observed in 14.8%. The most frequently observed grade 3 non-hematologic toxicity was anorexia (14.8%). The primary endpoint was not achieved. The results support a current consensus that the continuation of trastuzumab in second-line therapy for gastric cancer is not a recommended option." @default.
• W3165648618 created "2021-06-07" @default.
• W3165648618 creator A5000947818 @default.
• W3165648618 creator A5015096398 @default.
• W3165648618 creator A5016814013 @default.
• W3165648618 creator A5023481395 @default.
• W3165648618 creator A5032855161 @default.
• W3165648618 creator A5037645812 @default.
• W3165648618 creator A5041886510 @default.
• W3165648618 creator A5043020908 @default.
• W3165648618 creator A5048365357 @default.
• W3165648618 creator A5051645636 @default.
• W3165648618 creator A5054084673 @default.
• W3165648618 creator A5064504927 @default.
• W3165648618 creator A5069472371 @default.
• W3165648618 creator A5071947905 @default.
• W3165648618 creator A5076854153 @default.
• W3165648618 creator A5077310835 @default.
• W3165648618 creator A5078872795 @default.
• W3165648618 date "2021-01-01" @default.
• W3165648618 modified "2023-10-05" @default.
• W3165648618 title "Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203)" @default.
• W3165648618 cites W2008322008 @default.
• W3165648618 cites W2028358976 @default.
• W3165648618 cites W2034414538 @default.
• W3165648618 cites W2059755429 @default.
• W3165648618 cites W2097820456 @default.
• W3165648618 cites W2100439220 @default.
• W3165648618 cites W2104631255 @default.
• W3165648618 cites W2106777108 @default.
• W3165648618 cites W2111237964 @default.
• W3165648618 cites W2461672654 @default.
• W3165648618 cites W2572709096 @default.
• W3165648618 cites W2598685895 @default.
• W3165648618 cites W2639736062 @default.
• W3165648618 cites W2751869401 @default.
• W3165648618 cites W2802207314 @default.
• W3165648618 cites W2888462952 @default.
• W3165648618 cites W2889646458 @default.
• W3165648618 cites W2894279338 @default.
• W3165648618 cites W2899138638 @default.
• W3165648618 cites W2915300970 @default.
• W3165648618 cites W2976352116 @default.
• W3165648618 cites W3013862212 @default.
• W3165648618 cites W3147820834 @default.
• W3165648618 doi "https://doi.org/10.1620/tjem.254.49" @default.
• W3165648618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34053967" @default.
• W3165648618 hasPublicationYear "2021" @default.
• W3165648618 type Work @default.
• W3165648618 sameAs 3165648618 @default.
• W3165648618 citedByCount "1" @default.
• W3165648618 countsByYear W31656486182023 @default.
• W3165648618 crossrefType "journal-article" @default.
• W3165648618 hasAuthorship W3165648618A5000947818 @default.
• W3165648618 hasAuthorship W3165648618A5015096398 @default.
• W3165648618 hasAuthorship W3165648618A5016814013 @default.
• W3165648618 hasAuthorship W3165648618A5023481395 @default.
• W3165648618 hasAuthorship W3165648618A5032855161 @default.
• W3165648618 hasAuthorship W3165648618A5037645812 @default.
• W3165648618 hasAuthorship W3165648618A5041886510 @default.
• W3165648618 hasAuthorship W3165648618A5043020908 @default.
• W3165648618 hasAuthorship W3165648618A5048365357 @default.
• W3165648618 hasAuthorship W3165648618A5051645636 @default.
• W3165648618 hasAuthorship W3165648618A5054084673 @default.
• W3165648618 hasAuthorship W3165648618A5064504927 @default.
• W3165648618 hasAuthorship W3165648618A5069472371 @default.
• W3165648618 hasAuthorship W3165648618A5071947905 @default.
• W3165648618 hasAuthorship W3165648618A5076854153 @default.
• W3165648618 hasAuthorship W3165648618A5077310835 @default.
• W3165648618 hasAuthorship W3165648618A5078872795 @default.
• W3165648618 hasBestOaLocation W31656486181 @default.
• W3165648618 hasConcept C121608353 @default.
• W3165648618 hasConcept C126322002 @default.
• W3165648618 hasConcept C141071460 @default.
• W3165648618 hasConcept C143998085 @default.
• W3165648618 hasConcept C203092338 @default.
• W3165648618 hasConcept C2776283816 @default.
• W3165648618 hasConcept C2776694085 @default.
• W3165648618 hasConcept C2777063308 @default.
• W3165648618 hasConcept C2778850193 @default.
• W3165648618 hasConcept C2779786085 @default.
• W3165648618 hasConcept C2780739268 @default.
• W3165648618 hasConcept C2781190966 @default.
• W3165648618 hasConcept C31760486 @default.
• W3165648618 hasConcept C530470458 @default.
• W3165648618 hasConcept C535046627 @default.
• W3165648618 hasConcept C71924100 @default.
• W3165648618 hasConcept C90924648 @default.
• W3165648618 hasConceptScore W3165648618C121608353 @default.
• W3165648618 hasConceptScore W3165648618C126322002 @default.
• W3165648618 hasConceptScore W3165648618C141071460 @default.
• W3165648618 hasConceptScore W3165648618C143998085 @default.
• W3165648618 hasConceptScore W3165648618C203092338 @default.
• W3165648618 hasConceptScore W3165648618C2776283816 @default.
• W3165648618 hasConceptScore W3165648618C2776694085 @default.
• W3165648618 hasConceptScore W3165648618C2777063308 @default.
• W3165648618 hasConceptScore W3165648618C2778850193 @default.
• W3165648618 hasConceptScore W3165648618C2779786085 @default.

• next